Cargando…

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors

BACKGROUND: Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the constitutive tyrosine kinase (TK) activity of the BCR-ABL1 fusion protein. Accordingly, TK inhibitors have drastically changed the disease prognosis. However, persistence of the transformed hematopoiesis even in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mancini, M., De Santis, S., Monaldi, C., Bavaro, L., Martelli, M., Castagnetti, F., Gugliotta, G., Rosti, G., Santucci, M. A., Martinelli, G., Cavo, M., Soverini, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533706/ https://www.ncbi.nlm.nih.gov/pubmed/31122263 http://dx.doi.org/10.1186/s13046-019-1197-9

Ejemplares similares

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022)

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
por: Mancini, Manuela, et al.
Publicado: (2017)

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
por: Soverini, Simona, et al.
Publicado: (2018)

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016)

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
por: Bavaro, Luana, et al.
Publicado: (2019)

Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe
por: Li, Jingjing, et al.
Publicado: (2015)

Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors
por: Jadhav, Mrunal, et al.
Publicado: (2021)

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
por: Mancini, Manuela, et al.
Publicado: (2023)

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
por: Soverini, Simona, et al.
Publicado: (2016)

FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas
por: Dibb, M., et al.
Publicado: (2015)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Polo-Like Kinase-1 Controls Aurora A Destruction by Activating APC/C-Cdh1
por: van Leuken, Renske, et al.
Publicado: (2009)

Mitosis-specific phosphorylation of Mis18α by Aurora B kinase enhances kinetochore recruitment of polo-like kinase 1
por: Lee, Minkyoung, et al.
Publicado: (2017)

Polo-like kinase and Aurora B kinase phosphorylate and cooperate with the CIF1-CIF2 complex to promote cytokinesis initiation in Trypanosoma brucei
por: Kurasawa, Yasuhiro, et al.
Publicado: (2022)

Interdomain allosteric regulation of Polo kinase by Aurora B and Map205 is required for cytokinesis
por: Kachaner, David, et al.
Publicado: (2014)

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
por: Iezza, Miriam, et al.
Publicado: (2023)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
por: Martinelli, Giovanni, et al.
Publicado: (2009)

Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
por: Yang, Na, et al.
Publicado: (2019)

Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy
por: Martelli, Margherita, et al.
Publicado: (2020)

Drosophila Polo Kinase Is Required for Cytokinesis
por: Carmena, Mar, et al.
Publicado: (1998)

Concerted action of Aurora B, Polo and NHK-1 kinases in centromere-specific histone 2A phosphorylation
por: Brittle, Amy L., et al.
Publicado: (2007)

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia
por: Mancini, Manuela, et al.
Publicado: (2015)

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
por: Gavriilidis, Paschalis, et al.
Publicado: (2015)

Current treatment approaches in CML
por: Castagnetti, Fausto, et al.
Publicado: (2019)

Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora
por: Bruinsma, W, et al.
Publicado: (2017)

The balance of Polo-like kinase 1 in tumorigenesis
por: Lu, Lin-Yu, et al.
Publicado: (2009)

The CINs of Polo-Like Kinase 1 in Cancer
por: Cunningham, Chelsea E., et al.
Publicado: (2020)

Polo kinase: the choreographer of the mitotic stage?
Publicado: (1996)

Regulation of the polo kinase during cytokinesis
por: Kachaner, David
Publicado: (2015)

Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015)

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment
por: Monaldi, Cecilia, et al.
Publicado: (2021)

The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities
por: Bruno, Samantha, et al.
Publicado: (2021)

Aurora kinases in ovarian cancer
por: Pérez-Fidalgo, J Alejandro, et al.
Publicado: (2020)

Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma
por: Tavanti, E, et al.
Publicado: (2013)

Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020)

Polo-like kinase-1 in DNA damage response
por: Hyun, Sun-Yi, et al.
Publicado: (2014)

Polo-like kinase 1 as target for cancer therapy
por: Weiß, Lily, et al.
Publicado: (2012)

Polo-like kinase 1 promotes pulmonary hypertension
por: Chen, Rongrong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dll7770ggmipsf0nlcjunhfrqa